RE Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of the NASU, Kyiv 03022, Ukraine.
National Institute of Cancer, Ministry of Health of Ukraine, Kyiv 03022, Ukraine.
Exp Oncol. 2020 Jun;42(2):94-100. doi: 10.32471/exp-oncology.2312-8852.vol-42-no-2.14673.
The variability of the clinical course of prostate cancer (PC) indicates the need to find factors that could predict the aggressive potential of neoplasms accounting the biological characteristics of tumor cells. In this context, the role of NANOG, a transcription factor involved in maintaining pluripotency and one of the markers of cancer stem cells (CSCs), is being actively studied today.
To investigate the level of NANOG mRNA in tumor tissue of patients with PC and to analyze the possibility of its use as a marker of the disease course.
The study involved 85 patients with PC of stages II-IV. Morphological and immunohistochemical studies were performed on serial paraffin sections of resected PC using monoclonal antibodies to Ki-67 and androgen receptor. NANOG and miR-214 mRNA expression in tumor cells was analyzed by real-time reverse transcription polymerase chain reaction. The identification of CSCs was performed by double-labeled immunohistochemical method using primary antibodies to CD24 and CD44.
We have revealed notable variability of NANOG mRNA levels in tumor tissue of patients with PC (mean 4.18 ± 0.65 a.u. with individual deviations from 0.11 ± 0.03 a.u. to 15.24 ± 0.36 a.u.). According to NANOG mRNA levels, two groups of the PC patients were delineated: group 1 and group 2, with the average NANOG mRNA levels of 2.12 ± 0.16 a.u., and 8.68 ± 1.24 a.u., respectively. The NANOG mRNA levels in tumor tissue of PC patients of groups 1 and 2 correlated with preoperative serum prostate-specific antigen level (r = 0.58; p < 0.05 and r = 0.64; p < 0.05, respectively), tumor volume (r = 0.42; p < 0.05 and r = 0.72; p < 0.05, respectively), regional lymph node metastases (r = 0.70; p < 0.05 and r = 0.75; p < 0.05, respectively). High NANOG mRNA levels in tumor cells were associated with such molecular and biological features of PC as androgen receptor expression (r = 0.52; p < 0.05), high proliferative activity (r = 0.60; p < 0.05) and the presence of CSC markers (r = 0.75; p < 0.05).
The findings indicate that NANOG is involved in the formation of the PC malignancy and should be further studied as a potential marker for the prediction of the disease course.
研究 NANOG mRNA 在前列腺癌(PC)患者肿瘤组织中的水平,并分析其作为疾病进程标志物的可能性。
研究纳入 85 例 II-IV 期 PC 患者。对切除的 PC 连续石蜡切片进行形态学和免疫组织化学研究,使用抗 Ki-67 和雄激素受体的单克隆抗体。通过实时逆转录聚合酶链反应分析肿瘤细胞中 NANOG 和 miR-214 mRNA 的表达。通过使用针对 CD24 和 CD44 的原发性抗体的双标记免疫组织化学方法鉴定 CSC。
我们发现 PC 患者肿瘤组织中 NANOG mRNA 水平存在显著差异(平均 4.18 ± 0.65 a.u.,个体偏差为 0.11 ± 0.03 a.u.至 15.24 ± 0.36 a.u.)。根据 NANOG mRNA 水平,将两组 PC 患者分为:第 1 组和第 2 组,其平均 NANOG mRNA 水平分别为 2.12 ± 0.16 a.u.和 8.68 ± 1.24 a.u.。第 1 组和第 2 组 PC 患者肿瘤组织中的 NANOG mRNA 水平与术前血清前列腺特异性抗原水平相关(r = 0.58;p < 0.05 和 r = 0.64;p < 0.05),肿瘤体积(r = 0.42;p < 0.05 和 r = 0.72;p < 0.05),区域淋巴结转移(r = 0.70;p < 0.05 和 r = 0.75;p < 0.05)。肿瘤细胞中高 NANOG mRNA 水平与 PC 的分子和生物学特征相关,如雄激素受体表达(r = 0.52;p < 0.05),高增殖活性(r = 0.60;p < 0.05)和 CSC 标志物的存在(r = 0.75;p < 0.05)。
研究结果表明,NANOG 参与了 PC 恶性肿瘤的形成,应进一步作为疾病进程预测的潜在标志物进行研究。